DNLI
Denali TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Successful clinical readouts or a transformative partnership could validate Denali's pipeline and push valuation toward the high end of analyst ranges; upside supported by analyst highs (up to 50) and consensus averages above the current price [#SERP-5][#SERP-1].
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta 0.0.
What can break
Clinical trial failure or safety signal
Momentum
47
Value
41
Sentiment
100
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $31.50 · Bull $45.00 · Bear $18.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-02-26 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $32.93
Why
Momentum47 · Δ7d +14.4
Value41 · Δ7d +0.1
Sentiment100 · Δ7d 0.0
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Sentiment · See AI snapshot
Momentum
47
34% active weight
Current posture
7d trendFlat
Δ7d
+14.4
Δ21d
+10.3
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
100
33% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
0.0
Why this grade
Composite grade A. Momentum 47.3 / Value 41.1 / Sentiment 100.0
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$3.07B
Beta
1.02
Shares Out
155.77M
P/E (TTM) · Derived
-6.6
P/S (TTM)
-
P/FCF (TTM) · Derived
-8.22
Rev YoY
-100.0%
EPS YoY
-16.4%
Gross Margin
-
Op Margin
-37938.0%
Net Debt
-$822.99M
Current Ratio
9.79
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology